Isabel Desgagné-Penix of the Université du Québec à Trois-Rivières is a leading researcher in plant specialized metabolism. Her work aims to uncover the mysteries of alkaloid biosynthesis from medicinal plants, particularly plants within the Amaryllidaceae family, like narcissus or snowdrops, and to pioneer advancements in synthetic biology for metabolic engineering.

Her work has provided critical insights into the biosynthetic pathways of compounds like galanthamine, an alkaloid showing promise as an anti-Alzheimer's drug. Employing innovative approaches, Desgagné-Penix has developed a synthetic biology platform using microalgae for metabolite production. This platform serves as a miniature plant factory and has been adapted for manufacturing viral fragments and vaccine components, showcasing its versatility and societal impact during the COVID-19 pandemic.

Beyond her scientific contributions, Desgagné-Penix actively promotes diversity in STEM fields and engages with Indigenous communities, a testament to her commitment to equity and inclusion.

Desgagné-Penix's research promises to revolutionize drug discovery, agricultural practices, and biotechnological applications, offering tangible benefits to society through novel therapeutic compounds and sustainable production methods.